Radiofrequency-assisted Liver Resection in Intractable Liver Cancer

Completed

• Conditions: Liver Cancer
• Interventions: Procedure: TACE; Procedure: TACE+radiofrequency; Procedure: radiofrequency

• Registration Number: NCT04413526
• Lead Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province

Brief Summary

In this retrospective study, the investigators assessed the application of radiofrequency-assisted liver resection in intractable liver cancer resection, and plan to analysis the different factors.

Detailed Description

The primary clinical treatment of liver cancer is surgical resection, although many integrated applications develop rapidly, surgery is still the best way to remove the tumour lesion. Traditional ways that have curative removed tumours in three methods, which are liver resection, liver transplantation and radiofrequency ablation (RFA).

As for primary liver cancer, surgery, and RFA are both effective and safety, but for the complexity of end-stage liver cancer, surgical resection may not remove the tumours alone. Surgical resection with radiofrequency ablation therapy for intractable liver cancer is a kind of active plan. The therapy can eliminate the tumour, maximize the protection of patient liver tissue, reduce operation damage, reduce the incidence of complications, and improve patients quality of life after surgery.

Study Timeline

• Study Start: 2020-05-25
• Study First Submitted: 2020-05-25
• Study First Submitted QC: 2020-05-28
• Study First Posted: 2020-06-04
• Status Verified: 2021-11
• Primary Completion: 2021-11-18
• Study Completion: 2021-11-18
• Last Update Submitted: 2021-11-18
• Last Update Posted: 2021-11-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 199

Inclusion Criteria

• Ultrasound-guided fine-needle aspiration pathology or postoperative pathology was confirmed to be liver cancer, no pathological results according to China 's 2017 version of the hepatocarcinoma (HCC) diagnosis and treatment specifications, in line with the standard clinical diagnosis of liver cancer
• According to Barcelona Clinic Liver Cancer (BCLC) staging criteria, it is stage C (stage C: single tumour> 5 cm or more than three tumours, and at least one tumour> 3 cm, liver function Child-Pugh A or B, with lymph node metastasis or distant metastasis or portal vein or Venous liver trunk is invaded, penance Status (PST) score 1-2 points)

Exclusion Criteria

• HCC patients with other malignant tumours
• Metastatic liver tumour
• Patients with liver abscess
• Patients with organ dysfunction

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
TACE(transcatheter arterial chemoembolization)	TACE	temporary TACE for intractable liver cancer
radiofrequency ablation plus TACE	TACE+radiofrequency	radiofrequency ablation plus TACE for intractable liver cancer
radiofrequency-assisted liver resection	radiofrequency	radiofrequency-assisted liver resection for intractable liver cancer

Primary Outcome Measures

Name	Time	Method
The survival rates for one-year to five-year	5 years	The survival rates was defined as the percentage of liver cancer for five years.

Secondary Outcome Measures

Name	Time	Method
The Child-Pugh score after therapy	3 months	The Child-Pugh is based on the presence and severity of ascites and hepatic encephalopathy, the prolongation of prothrombin time, and the levels of serum bilirubin and albumin. According to the Child-Pugh scores, patients are classified into three classes (Child class A, B, and C with CP scores 5-6, 7-9, and 10-15, respectively)
The hospital stay	3 months	The length of stay in a hospital regarding days

Trial Locations

Locations (1)

Hepatopancreatobiliary Surgery Institute of Gansu Province; 🇨🇳 Lanzhou, Gansu, China